Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The company has a market […]
More Stories
SuRo Capital (NASDAQ:SSSS) & BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM) Head to Head Analysis
BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM – Get Free Report) and SuRo Capital (NASDAQ:SSSS – Get Free Report) are...
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...